Niacin (Flush-Free).

Flush-free niacin is normally inositol hexanicotinate, six nicotinic acid molecules esterified to one inositol. Hydrolysis releases both, so an inositol entry alongside it is the same molecule twice.

The ester hydrolyses slowly to free nicotinic acid, which is why the skin flush is muted rather than absent. Combining it with plain niacin adds to one nicotinic acid total.

Niacinamide and released nicotinic acid both terminate in the NAD pool, through the salvage and Preiss-Handler routes respectively. Their vitamin B3 amounts count together against intake limits.

Once hydrolysed, the nicotinic acid from the ester is converted to nicotinic acid mononucleotide and then to NAD. The two entries raise a single dinucleotide pool.

Tryptophan supplies niacin equivalents through the kynurenine pathway at roughly 60 to 1. It adds to the same vitamin total the ester eventually delivers.

The tryptophan route to niacin runs through the pyridoxal-phosphate enzyme kynureninase. B6 status therefore decides how much niacin comes from protein rather than from the supplement.

FAD-dependent kynurenine monooxygenase is a required step in making niacin from tryptophan. Riboflavin sits inside the same pathway as a cofactor, not as an additional source.

Clearing surplus B3 requires methylation to N-methylnicotinamide, drawing on S-adenosylmethionine. Trimethylglycine replenishes methyl groups so that route is not the limiting factor.

S-adenosylmethionine is the direct methyl donor consumed when B3 is methylated for excretion. Higher B3 intakes draw on that same pool.

Chromium is often supplied bound to nicotinic acid as chromium polynicotinate, so nicotinate chemistry and chromium turn up in the same product by design. The nicotinate acts as the ligand that carries the mineral rather than as an independent active at that dose. This is formulation convention with a chemical basis, not a tested combination.

Nicotinamide is cleared partly by N methylation, a reaction that consumes S adenosylmethionine. Regenerating that methyl donor runs through the folate cycle, so higher nicotinate intake raises demand on one carbon supply. Folate supports the normal remethylation step that keeps the donor pool turning over.

Methionine synthase needs B12 to move a methyl group from folate onto homocysteine, regenerating methionine and then S adenosylmethionine. Since nicotinamide disposal spends methyl groups, B12 sits on the resupply side of the same ledger. The relationship is metabolic accounting rather than a measured combination effect.

Methionine is the direct precursor of S adenosylmethionine, the methyl donor used by nicotinamide N methyltransferase. Adequate methionine supply is what allows that clearance route to run without drawing down the donor pool. Very high nicotinate intakes are the situation where this matters, not ordinary ones.

Choline oxidised to betaine donates a methyl group to homocysteine through betaine homocysteine methyltransferase, an alternative to the folate route. It is therefore a second source of methyl groups when nicotinamide methylation is drawing on the pool. The link is biochemical, and no combination trial measures the two together.

Nicotinic acid enters NAD synthesis through the Preiss Handler route while nicotinamide riboside enters through nicotinamide riboside kinase. Both converge on the same NAD pool, so combining them stacks precursors on one endpoint rather than opening a new one. Total vitamin B3 equivalents across a formula are worth reading as one number.

NMN feeds the same NAD pool as nicotinic acid derived precursors, just one step further along the salvage route. Combining them is additive on the endpoint rather than complementary in mechanism. No combination trial has measured the pair.

Both immediate release nicotinic acid and marine omega 3 fatty acids lower circulating triglycerides, by different routes: nicotinic acid through adipose lipolysis suppression and hepatic output, omega 3 through reduced very low density lipoprotein assembly. Circulating triglycerides are a marker. Whether the flush free ester reaches plasma nicotinic acid concentrations high enough to contribute is not established, so the additive framing applies to nicotinic acid rather than to this form specifically.

Red yeast rice supplies monacolin K, which inhibits hepatic cholesterol synthesis, while nicotinic acid acts on lipoprotein handling from a different angle. The two have been combined in lipid marker studies of immediate release nicotinic acid. Blood lipids are markers rather than outcomes, and the flush free ester was not the material tested.

Berberine increases hepatic LDL receptor expression and has been studied for its effect on circulating lipid markers. Its route differs from that of nicotinic acid, so the two are combined in lipid marker formulas. This is an association across separate literatures rather than a measured combination, and lipid values are markers.

Viscous soluble fibre binds bile acids and increases their loss, which draws on hepatic cholesterol. Nicotinic acid acts on lipoprotein production and clearance instead, so the two act at different points. Marker level literature supports each separately, not the pair.

Fatty acid oxidation, which carnitine enables by carrying acyl groups into mitochondria, generates reducing equivalents that need NAD as the acceptor. NAD availability therefore sits downstream of B3 supply. The connection is pathway level rather than a demonstrated combination, and it supports normal energy yielding metabolism.